CY1108817T1 - Ανοσολογικη θεραπεια για την αντιμετωπιση της αθηροσκληρωσης - Google Patents

Ανοσολογικη θεραπεια για την αντιμετωπιση της αθηροσκληρωσης

Info

Publication number
CY1108817T1
CY1108817T1 CY20091100202T CY091100202T CY1108817T1 CY 1108817 T1 CY1108817 T1 CY 1108817T1 CY 20091100202 T CY20091100202 T CY 20091100202T CY 091100202 T CY091100202 T CY 091100202T CY 1108817 T1 CY1108817 T1 CY 1108817T1
Authority
CY
Cyprus
Prior art keywords
treatment
athleticosis
immunological
cardiovascular disease
peptides
Prior art date
Application number
CY20091100202T
Other languages
Greek (el)
English (en)
Inventor
Jan Nilsson
Prediman K Shah
Original Assignee
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Forskarpatent I Syd Ab filed Critical Forskarpatent I Syd Ab
Publication of CY1108817T1 publication Critical patent/CY1108817T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CY20091100202T 2001-04-05 2009-02-24 Ανοσολογικη θεραπεια για την αντιμετωπιση της αθηροσκληρωσης CY1108817T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
EP02714667A EP1383526B1 (en) 2001-04-05 2002-04-05 Immunization therapy for treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
CY1108817T1 true CY1108817T1 (el) 2014-04-09

Family

ID=26655437

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100202T CY1108817T1 (el) 2001-04-05 2009-02-24 Ανοσολογικη θεραπεια για την αντιμετωπιση της αθηροσκληρωσης

Country Status (18)

Country Link
EP (42) EP2295463A1 (enExample)
JP (6) JP2004529143A (enExample)
CN (4) CN101486766A (enExample)
AT (2) ATE415423T1 (enExample)
AU (1) AU2002246484B8 (enExample)
BR (1) BR0208685A (enExample)
CA (3) CA2606839C (enExample)
CY (1) CY1108817T1 (enExample)
DE (1) DE60230029D1 (enExample)
DK (3) DK2006301T3 (enExample)
EE (2) EE200300487A (enExample)
ES (2) ES2546293T3 (enExample)
IL (4) IL158285A0 (enExample)
PL (4) PL215401B1 (enExample)
PT (1) PT1383526E (enExample)
RU (1) RU2296582C2 (enExample)
SE (1) SE0103754L (enExample)
WO (1) WO2002080954A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
SI1735349T1 (sl) * 2004-04-15 2010-12-31 Athera Biotechnologies Ab Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov
EP1676602A1 (en) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
MX2009006744A (es) * 2006-12-22 2009-06-30 Abbott Lab Panel de padecimiento cardiovascular autoinmune y metodos de utilizacion del mismo.
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
EP2538218A3 (en) * 2007-11-05 2013-04-24 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2319924B1 (en) * 2008-08-15 2016-03-09 Fujikura Kasei Co., Ltd. Polypeptide marker for diagnosis of arteriosclerosis, method for detection of arteriosclerosis by using the maker or the like, and kit for diagnosis of arteriosclerosis
AU2010319323B2 (en) 2009-11-14 2015-01-15 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) * 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
WO2012024309A2 (en) 2010-08-18 2012-02-23 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
JP2013544243A (ja) * 2010-11-12 2013-12-12 シーダース シナイ メディカル センター 動脈瘤の治療及び／又は予防のための免疫調節方法及びシステム
AU2011325948A1 (en) * 2010-11-12 2013-05-30 Cedars-Sinai Medical Center Immunomodulatory compositions, methods and systems comprising immunogenic fragments of Apob100
WO2012074725A2 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
EP2741770A4 (en) 2011-08-09 2014-12-31 Athera Biotechnologies Ab ANTIBODY BINDING TO PHOSPHORYLCHOLIN (PC) AND / OR PC CONJUGATES
LT2742068T (lt) 2011-08-09 2019-07-10 Athera Biotechnologies Ab Nauji antikūnai prieš fosforilcholiną
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
US10087234B2 (en) 2012-11-06 2018-10-02 Les Hopitaux Universitaires De Geneve Mimetic peptides
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
EP3297652A4 (en) * 2015-05-19 2019-06-05 La Jolla Institute for Allergy and Immunology HUMAN APOB100 EPITOPES, METHOD AND USES FOR MODULATING INFLAMMATORY REACTIONS AND TREATING UNWANTED CARDIOVASCULAR EVENTS, DISEASES AND ATHEROSCLEROSIS
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
WO2019232070A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of psoriasis
WO2019232081A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis
CN115025210B (zh) * 2021-03-05 2025-09-05 香港中文大学 减少动脉粥样硬化进展的肽疫苗组合物和药物制剂
CN115025211A (zh) * 2021-11-02 2022-09-09 南京理工大学 用于动脉粥样硬化治疗的纳米疫苗及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (en) * 1992-03-06 1993-09-16 Abbott Laboratories Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
EP0911344B1 (en) * 1997-10-15 2004-03-03 Fujirebio Inc. Anti-Apo-B-48 monoclonal antibody, hybridoma, and methods of use
AU760794B2 (en) * 1998-03-10 2003-05-22 Regents Of The University Of California, The Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
WO2000002920A1 (en) * 1998-07-13 2000-01-20 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
AU773370B2 (en) * 1999-10-26 2004-05-20 Regents Of The University Of California, The Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
EP1290217A2 (en) * 2000-02-04 2003-03-12 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
ES2219517T3 (es) * 2000-03-03 2004-12-01 Glaxosmithkline Biologicals S.A. Vacuna para el tratamiento de la aterosclerosis.
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
EP1592445A4 (en) * 2000-10-25 2007-01-10 Vincent Agnello METHOD FOR INHIBITING HEPATITIS C VIRUS (HCV) INFECTION AND OTHER FLAVIRIDAE / I FAMILY VIRUSES, AND OTHER BLOODY-VIRUSES COMPLEXING WITH LOW OR VERY LOW DENSITY LIPOPROTEIN DENSITY, BY PREVENTING VIRAL ENTRY IN A CELL
WO2002042426A2 (en) * 2000-11-10 2002-05-30 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
RU2003136090A (ru) * 2001-05-15 2005-04-20 Джэпэн Иммьюнорисерч Лэборэтериз Ко., Лтд (Jp) Пептид, взаимодействующий с липопротеином высокой плотности
CA2454418A1 (en) * 2001-07-20 2003-01-30 Eidgenoessische Technische Hochschule Zurich (Ethz) Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids

Also Published As

Publication number Publication date
EP1383526B1 (en) 2008-11-26
EP2289933A1 (en) 2011-03-02
EP1383526A1 (en) 2004-01-28
EP2289934A1 (en) 2011-03-02
EP2295457A1 (en) 2011-03-16
DE60230029D1 (de) 2009-01-08
EP2006301A1 (en) 2008-12-24
ES2546293T3 (es) 2015-09-22
EP1918300A3 (en) 2009-06-17
PT1383526E (pt) 2009-02-27
CN101284874B (zh) 2012-10-03
SE0103754L (sv) 2002-10-06
EP2295460A1 (en) 2011-03-16
EP2289918A1 (en) 2011-03-02
AU2002246484A1 (en) 2002-10-21
EP1918300A2 (en) 2008-05-07
EP2295464B1 (en) 2015-06-03
EP2147930A3 (en) 2010-04-14
EP2147930A2 (en) 2010-01-27
EP2147928A2 (en) 2010-01-27
EP2289920A1 (en) 2011-03-02
PL400308A1 (pl) 2012-12-17
PL217858B1 (pl) 2014-08-29
EP2147680A2 (en) 2010-01-27
AU2002246484B2 (en) 2007-04-19
EE200700052A (et) 2008-08-15
CA2606839A1 (en) 2002-10-17
IL188286A0 (en) 2008-03-20
CN101486766A (zh) 2009-07-22
EP2289922A1 (en) 2011-03-02
SE0103754D0 (sv) 2001-11-09
EP2289916A1 (en) 2011-03-02
EP2147929A2 (en) 2010-01-27
EP2289929A1 (en) 2011-03-02
EP2289914A1 (en) 2011-03-02
JP2008169215A (ja) 2008-07-24
BR0208685A (pt) 2004-03-30
EP2289932A1 (en) 2011-03-02
WO2002080954A1 (en) 2002-10-17
EP2289928A1 (en) 2011-03-02
DK2006301T3 (da) 2011-09-12
JP2013144687A (ja) 2013-07-25
JP5270456B2 (ja) 2013-08-21
ES2317999T3 (es) 2009-05-01
EP2289915A1 (en) 2011-03-02
IL158285A (en) 2009-12-24
ATE415423T1 (de) 2008-12-15
JP2011063598A (ja) 2011-03-31
EP2295460B1 (en) 2015-06-03
EP2147928A3 (en) 2010-04-14
DK2295464T3 (en) 2015-08-17
EP2289934B1 (en) 2013-11-13
CA2443223C (en) 2013-11-26
IL195356A0 (en) 2009-08-03
JP5613890B2 (ja) 2014-10-29
RU2003132443A (ru) 2005-02-27
EP2295462A1 (en) 2011-03-16
EP2147680A3 (en) 2010-04-14
EP2147929A3 (en) 2010-04-14
RU2296582C2 (ru) 2007-04-10
CN103122031B (zh) 2015-07-22
DK1383526T3 (da) 2009-03-30
EE200300487A (et) 2004-02-16
CA2443223A1 (en) 2002-10-17
JP2011068654A (ja) 2011-04-07
EP2305708A1 (en) 2011-04-06
EP2289935A1 (en) 2011-03-02
CN1505525B (zh) 2012-11-07
EP2295461A1 (en) 2011-03-16
EP2295464A1 (en) 2011-03-16
CN101284874A (zh) 2008-10-15
EP2295459A1 (en) 2011-03-16
AU2002246484B8 (en) 2007-06-14
CN1505525A (zh) 2004-06-16
PL367301A1 (en) 2005-02-21
EP2006301B1 (en) 2011-05-25
EP2305707A1 (en) 2011-04-06
EP2289925A1 (en) 2011-03-02
EP2289924A1 (en) 2011-03-02
PL215401B1 (pl) 2013-12-31
JP2009191078A (ja) 2009-08-27
EP2289931A1 (en) 2011-03-02
EP2289927A1 (en) 2011-03-02
JP2004529143A (ja) 2004-09-24
EP2289913A1 (en) 2011-03-02
EP2289921A1 (en) 2011-03-02
CA2827167A1 (en) 2002-10-17
EP2289926A1 (en) 2011-03-02
CA2606839C (en) 2015-06-09
EP2289930A1 (en) 2011-03-02
EP2305706A1 (en) 2011-04-06
EP2289912A1 (en) 2011-03-02
JP5300820B2 (ja) 2013-09-25
JP5300819B2 (ja) 2013-09-25
ATE510851T1 (de) 2011-06-15
EP2289917A1 (en) 2011-03-02
EP2289919A1 (en) 2011-03-02
EP2289923A1 (en) 2011-03-02
EP2295458A1 (en) 2011-03-16
CN103122031A (zh) 2013-05-29
EP2295463A1 (en) 2011-03-16
IL158285A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
CY1125133T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα a il-17
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
CY1122346T1 (el) Μονοκλωνα αντισωματα εναντι tης κλαουδινης 18 για τη θεραπεια του καρκινου
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
CY1116167T1 (el) Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1
CY1117756T1 (el) Χιμαιρικα υβριδια μονομερους-διμερους ανοσοσφαιρινης
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
BRPI0411854A (pt) veìculos protéicos para vacinas
CY1117617T1 (el) Αντισωματα ige εναντι ανθρωπου υψηλης συναφειας
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CY1118420T1 (el) Αντι-ιδιοτυπικο αντισωμα εναντι ενος αντισωματος εναντι του βητα αμυλοειδους πεπτιδιου
PE20071055A1 (es) Anticuerpos anti mn
ATE263189T1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
PE20080891A1 (es) Anticuerpos anti-notch3 y composiciones que los comprenden
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna